Evidence map›Paper›PMID 31076698›Full record

SynthesisBritish dental journal2019

A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism.

Jalpesh Patel, Jorge A Cardoso, Shamir Mehta

3 registry-linked trialsAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in British dental journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05562531 unknown statusnot on this mapstarted 2022, after this paper: background citation

Evaluation of the Chewing Performance and Nutritional Status of the Patients Diagnosed With Bruxism After Botulinum Toxin Application: Follow-up Study

Typeobservational_patient_registrySponsorMarmara UniversityRan2022 to 2023Enrolled30ConditionsTemporomandibular Disorder, Bruxism
NCT05651256 phase2 / phase3completednot on this mapstarted 2021, after this paper: background citation

Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: A Randomized Clinical Trial

TypeinterventionalSponsorUniversity of SalamancaRan2021 to 2021Enrolled20ConditionsTemporomandibular Joint Disorder BilateralArmsBotulinum toxin type A injection
NCT06677216 enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Botulinum Toxin in the Management of Temporo-mandibular Related Myalgia: a Prospective Study

TypeobservationalSponsorDiakonessenhuis, UtrechtRan2024 to 2025Enrolled30ConditionsTMD/Orofacial Pain, Myalgia of Mastication Muscle, Botulinum Toxin, Type aArmsBotulinum Toxin, Type A
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Temporomandibular joint injection therapy.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jalpesh PatelFairlands Dental and Implant Centre, Fairlands Avenue, Guildford, Surrey, UK. contact@jalpeshpatel.co.uk.
Jorge A CardosoORA, Estética e Reabilitação Oral, Espinho, Portugal.
Shamir MehtaKings College London Dental Institute, Department of Conservative Dentistry, Unit of Distance Learning, Floor 18, Tower Wing, Guy's Campus, St Thomas Street, London, UK.
King's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction The medical and cosmetic use of botulinum toxin (BTX) is now widespread. With an increased number of clinicians adopting the use of BTX in the management of temporomandibular disorders (TMD) and/or bruxism, as either a standalone treatment or as an adjunct, affirmation is required in regards to whether it has a clinically justifiable position among the current spectrum of available treatment modalities.Objectives To establish the usefulness of BTX when treating patients with TMD and/or bruxism, and thereby determine whether there may be an appropriate purpose for the prescription of BTX in the management of these patients.Data sources and data selection A systematic review of the relevant literature was conducted. The literature search was carried out by applying key terms to appropriate data sources (Medline, Embase, Pubmed, Cochrane Central Register of Controlled Trials, and OpenSIGLE). The resultant papers were subjected to inclusion and exclusion criteria, which were then assessed for bias using a framework outlined in the Cochrane Handbook.Results A total of 11 trials met the inclusion criteria. The primary outcome measure was changes in pain experience in groups that had been treated with BTX, relative to an appropriate control group. Secondary outcomes included changes in the frequency of bruxism events, changes in maximum mouth opening, changes in occlusal force and changes in electromyography (EMG) readings of muscles of mastication.Conclusion The evidence to support the use of BTX in the management of TMD and/or bruxism is not entirely unequivocal. A number of studies that have met the inclusion criteria have shown promising results and thereby justify further investigation. Given the current evidence, BTX should certainly be considered but due to financial implications and possible side effects, it seems appropriate that conservative options, such as self-management with explanation and physical therapies, should be exhausted first.

Indexed as

Botulinum Toxins, Type ABruxismNeuromuscular AgentsTemporomandibular Joint DisordersHumansMasticationBotulinum Toxins, Type ANeuromuscular Agents

Identifiers

PMID31076698
OpenAlexW2944620429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.